Research Update

Summary by AI BETAClose X

Scancell Holdings Plc announced positive Phase 2 data for its iSCIB1+ Immunobody® DNA active immunotherapy in late-stage melanoma, presented at SITC 2025. The SCOPE trial demonstrated an 11-month progression-free survival (PFS) of 78% in the target population, significantly exceeding the historic 12-month PFS of 46% for doublet checkpoint therapy. Furthermore, combined data for the HLA target population showed a 22-month PFS of 69%, alongside superior overall response and disease control rates with a favourable safety profile across over 100 patients. These compelling results accelerate development plans, including regulatory and partnering discussions, with randomised studies anticipated to begin in 2026, potentially expanding the addressable patient population to 80% of late-stage melanoma patients.

Disclaimer*

UK 100

Latest directors dealings